Clinical trials: Colorectal Cancer Liver Metastasis
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Cancer Colorectal
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.
- Trial name
- CETIDYL (NCT04189055)
- Testing
- Cetuximab, Irinotecan
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Cancer With Hepatic Metastases
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
- Trial name
- NCT07357220
- Testing
- VG2025, AK112
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Akeso
Unresectable Liver Metastasis of Colorectal Cancer
Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer
The purpose of this study is to investigate whether TAC plus FOLFOX4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given FOLFOX4 only.
- Trial name
- NCT00869271
- Testing
- tac + folfox4, Folfox4
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic, Colorectal Cancer
TheraSphere® For Treatment of Metastases in Liver
To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.
- Trial name
- NCT04517643
- Testing
- Therasphere Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer Liver Metastasis
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether RFA is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in overall survival compared with chemotherapy (target…
- Trial name
- NCT03127072
- Testing
- Radiofrequency Ablation (RFA), chemotherapy ± target therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Cancer, Metastatic Liver Cancer
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Recurrence of liver metastasis in colorectal cancer after R0 resection is mainly due to the invisible minimal residual disease, which are the main factors leading to metastasis and recurrence.
- Trial name
- NCT05240950
- Testing
- Anti-CEA CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
Cancer of Colon, Metastasis to Liver
Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer
Analyze the dynamics of incorporation of 5-fluorouracil into cancer cell ribosomes from liver metastases of patient with metastatic colon cancer.
- Trial name
- FLUORIB (NCT04274790)
- Testing
- Scheduled and planned surgery
- Where
- France
- Sponsor
- Centre Leon Berard
Liver Metastasis
Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3)
This study is designed to see whether stereotactic body radiation therapy (SBRT) can reduce tumour size, slow progression of the disease, prolong life and improve quality of life.
- Trial name
- NCT00914615
- Testing
- Stereotactic Body Radiation
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation
Multiple articles report that thermal ablation is a safe and effective treatment for unresectable colorectal liver metastases (CRLM) ≤3cm. However efficacy of thermal ablation decreases with increasing lesion size.
- Trial name
- COLLISION-XL (NCT04081168)
- Testing
- Stereotactic Body Radiotherapy, Microwave Ablation
- Where
- Netherlands
- Volunteers
- 68 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Colorectal Cancer, Circulating Tumor DNA
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of…
- Trial name
- CLIMES (NCT05787197)
- Where
- 16 sites in France
- Volunteers
- 232 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Hepatic Metastases, Colon Cancer
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus…
- Conditions
- Hepatic Metastases, Colon Cancer, Rectal Cancer
- Trial name
- NCT00200200
- Testing
- Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
- Trial name
- NCT03577665
- Testing
- curative proton therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Colorectal Cancer, Liver Metastases
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in…
- Trial name
- NCT06280495
- Testing
- Oxaliplatin, Fluorouracil, Serplulimab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from cancer. Between 30 to 60% of patients develop limited or predominant liver metastases.
- Trial name
- OSCAR (NCT02885753)
- Testing
- Oxaliplatin intravenous, 5 FU bolus, Folinic acid
- Where
- 49 sites in Belgium, France
- Volunteers
- 348 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Liver Cancer
Resveratrol and Human Hepatocyte Function in Cancer
The purpose of this study is to determine if Resveratrol, a nutritional supplement, shows a beneficial effect in the cellular function of normal liver cells and diseased liver cells (cancer cells) in samples of liver tissue taken…
- Trial name
- NCT02261844
- Testing
- Resveratrol
- Where
- United States
- Sponsor
- University of Louisville
Colorectal Cancer
Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases.
- Trial name
- ARF2003 (NCT00210106)
- Testing
- Ablathermy
- Where
- 12 sites in France
- Volunteers
- 52 people
- Sponsor
- Institut Bergonié
Liver Metastases, Colorectal Cancer
Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
The role of radiotherapy in metastatic cancer has historically been limited to palliation while metastasectomy or radiofrequency has emerged as playing a major role in disease control.
- Trial name
- OLIVER (NCT03532204)
- Testing
- SBRT, Chemotherapy
- Sponsor
- UNICANCER
Colo-rectal Cancer
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.
This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as…
- Trial name
- NCT07515963
- Testing
- FULIRI combination targeted therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhongnan Hospital